Adam Turpcu

Company: Adverum Biotechnologies

Job title: SVP

Bio:

Adam Turpcu serves as Senior Vice President of Clinical Development at Adverum Biotechnologies, where he has contributed for six years to advancing gene therapy for ophthalmic disorders. With diverse expertise spanning clinical development, medical affairs, health economics, and commercial marketing, Adam has been instrumental in designing and executing Adverum’s clinical program from Phase I through Phase III trials. He led the design of the company’s first human study and currently oversees the Phase II LUNA trial and Phase III ARTEMIS trial for wet AMD treatment. Previously, Adam held positions at Clearside Biomedical and Genentech, bringing extensive experience in ophthalmology drug development and regulatory strategy.

Seminars:

Pioneering Intravitreal Gene Therapy for Wet AMD: 7 Years of Clinical Experience from Phase 1 to Phase 3 11:30 am

Examining key learnings from early-stage intravitreal gene therapy studies and how these learnings impacted late-stage study design Highlighting key efficacy and safety data from the phase 1 OPTIC and phase 2 LUNA studies Exploring an end-to-end journey of one of the first patients dosed with Ixo-vec  Read more

day: Conference Day One